top
Please input keywords
파이프라인
다양한 타겟에 대한 임상/전임상 파이프라인
바이오사이토젠은 환자의 수요를 만족시키는 혁신적인 항체 신약 개발을 위하여, 항암, 자가면역질환, 대사질환, 감염질환 등의 다양한 질병 영역에서 독자적이며 혁신적인 신약개발 능력을 활용하여 단일클론항체, 이중특이성항체, ADC 등을 포함한 십여개의 연구개발중인 파이프라인을 보유하고 있습니다. 강력한 임상개발팀과 풍부한 임상자원을 바탕으로, 잠재력있는 파이프라인의 개발을 가속화하여 신약의 임상 개발 과정을 앞당기고 있습니다.
Therapeutic Area
Product
Target(s)
Partner
Molecular Format
Indication(s)
Status
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Oncology
YH003
CD40
mAb
Solid tumors
More
YH001
CTLA-4
TRACON
mAb
Solid tumors
More
YH002
OX40
mAb
Solid tumors
More
YH004
4-1BB
mAb
Solid tumor + Hematological malignancy
More
YH005-ADC
Claudin18.2- ADC
Remegen
ADC
More
YH008
PD-1 x CD40
Chipscreen NewWay
BsAb
Solid tumors
More
YH012
HER2 x TROP2
BsADC
Solid tumors
More
YH013
EGFR x MET
BsADC
Solid tumors
More
YH016
Undisclosed
Oncology
BCG003
TNFR2
Dragonboatbio
mAb
Solid tumors
More
BCG008
SIGLEC15
Undisclosed
mAb
Solid tumors
More
BCG011
TROP2 x EGFR
Undisclosed
BsADC
Oncology
BCG012
HER3 x MUC1
Undisclosed
BsADC
Oncology
BCG001
B7-H3
Mabworks
mAb
Solid tumors
More
BCG005
CCR8
LiberoThera
mAb
Solid tumors
BCG007
AMHR2
Undisclosed
mAb
Solid tumors
BCG002
CD24
mAb
Solid tumors
BCG006
WT1
Undisclosed
TCRm
Oncology
BCG010
NKG2A
Undisclosed
mAb
Oncology
BCG013
5T4 x MET
Undisclosed
BsADC
Oncology
Inflammation and Autoimmunity
YH015
CD40 inhibitor
mAb
Autoimmunity
More
YH017
Undisclosed
Autoimmunity
Infectious Diseases
BCG004
Rabies virus
Undisclosed
mAb
Infectious Diseases
Rare Diseases
BCG009
Undisclosed
Undisclosed
mAb
Rare diseases
Oncology
YH003
More
Target:
CD40
Partner:
Molecular Format:
mAb
Indication:
Solid tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH001
More
Target:
CTLA-4
Partner:
TRACON
Molecular Format:
mAb
Indication:
Solid tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH002
More
Target:
OX40
Partner:
Molecular Format:
mAb
Indication:
Solid tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH004
More
Target:
4-1BB
Partner:
Molecular Format:
mAb
Indication:
Solid tumor + Hematological malignancy
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH005-ADC
More
Target:
Claudin18.2- ADC
Partner:
Remegen
Molecular Format:
ADC
Indication:
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH008
More
Target:
PD-1 x CD40
Partner:
Chipscreen NewWay
Molecular Format:
BsAb
Indication:
Solid tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH012
More
Target:
HER2 x TROP2
Partner:
Molecular Format:
BsADC
Indication:
Solid tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH013
More
Target:
EGFR x MET
Partner:
Molecular Format:
BsADC
Indication:
Solid tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH016
More
Target:
Undisclosed
Partner:
Molecular Format:
Indication:
Oncology
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG003
More
Target:
TNFR2
Partner:
Dragonboatbio
Molecular Format:
mAb
Indication:
Solid tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG008
More
Target:
SIGLEC15
Partner:
Undisclosed
Molecular Format:
mAb
Indication:
Solid tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG011
More
Target:
TROP2 x EGFR
Partner:
Undisclosed
Molecular Format:
BsADC
Indication:
Oncology
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG012
More
Target:
HER3 x MUC1
Partner:
Undisclosed
Molecular Format:
BsADC
Indication:
Oncology
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG001
More
Target:
B7-H3
Partner:
Mabworks
Molecular Format:
mAb
Indication:
Solid tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG005
More
Target:
CCR8
Partner:
LiberoThera
Molecular Format:
mAb
Indication:
Solid tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG007
More
Target:
AMHR2
Partner:
Undisclosed
Molecular Format:
mAb
Indication:
Solid tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG002
More
Target:
CD24
Partner:
Molecular Format:
mAb
Indication:
Solid tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG006
More
Target:
WT1
Partner:
Undisclosed
Molecular Format:
TCRm
Indication:
Oncology
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG010
More
Target:
NKG2A
Partner:
Undisclosed
Molecular Format:
mAb
Indication:
Oncology
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG013
More
Target:
5T4 x MET
Partner:
Undisclosed
Molecular Format:
BsADC
Indication:
Oncology
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Inflammation and Autoimmunity
YH015
More
Target:
CD40 inhibitor
Partner:
Molecular Format:
mAb
Indication:
Autoimmunity
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH017
More
Target:
Undisclosed
Partner:
Molecular Format:
Indication:
Autoimmunity
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Infectious Diseases
BCG004
More
Target:
Rabies virus
Partner:
Undisclosed
Molecular Format:
mAb
Indication:
Infectious Diseases
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Rare Diseases
BCG009
More
Target:
Undisclosed
Partner:
Undisclosed
Molecular Format:
mAb
Indication:
Rare diseases
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
바이오사이토젠은 이미 전 세계의 여러 제약회사들과 완전 인간 항체 생산 마우스 플랫폼의 사용 계약과 항체신약 개발의 파트너쉽을 체결하였습니다. 파트너쉽에 대해 더 알아보시려면 아래를 클릭해주세요.

파이프라인과 관련된 합작 문의 : bd@eucure.com
합작연구개발
naver-site-verification: naver8a6b0412e3d2d9dd38f1684b831435ac.html